Global Ai In Bioinformatics Market
Market Size in USD Billion
CAGR :
% 
USD
2.53 Million
USD
3.20 Million
2022
2030
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 2.53 Million |
 Market Size (Forecast Year) |
USD 3.20 Million |
 CAGR |
% |
| Major Markets Players |
|
Global AI in Bioinformatics Market, By Offering (Software, Services, Others), Type (Machine Learning, Deep Learning and Others), Products and Services (Knowledge Management Tools, Bioinformatics Platforms, Bioinformatic organizationpplication (Genomics, Microarrays, System Biology, Text Mining, Chemoinformatics & Drug Design, Proteomics, Transcriptomics, DNA Sequencing, Metabolomics, Others), Sector (Medical Biotechnology, Animal Biotechnology, Plant Biotechnology, Environmental Biotechnology, Forensic Biotechnology, Others) - Industry Trends and Forecast to 2030.
AI in Bioinformatics Market Analysis and Size
The reduction in the genetic sequencing cost has enhanced the demand of the market. The rising healthcare expenditure for better health services is also attributed to the growth of the market. The major market players are highly focused on various service launches and service approvals during this crucial period. In addition, the growing demand for bioinformatics and increasing public-private sector funding for bioinformatics are also contributing to the rising demand for the market.
The AI in bioinformatics market is growing in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The increasing advancements in bioinformatics technology are further boosting the market growth. However, the high cost of instrumentations and cybersecurity concerns in bioinformatics might hamper the growth of the AI in bioinformatics market in the forecast period.
Data Bridge Market Research analyzes that the global AI in bioinformatics market is valued at USD 2.53 million in 2022 and is expected to reach USD 217.38 million by 2030, registering a CAGR of 42.7% during the forecast period of 2023-2030. “Services" accounts for the largest technology segment in the AI in bioinformatics market due to rapid developments in technological pathways to commercialize the use of handheld AI in bioinformatics. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Offering (Software, Services, Others), Type (Machine Learning, Deep Learning, Others), Products and Services (Knowledge Management Tools, Bioinformatics Platforms, Bioinformatic Services), Application (Genomics, Microarrays, System Biology, Text Mining, Chemoinformatics & Drug Design, Proteomics, Transcriptomics, DNA Sequencing, Metabolomics, Others), Sector (Medical Biotechnology, Animal Biotechnology, Plant Biotechnology, Environmental Biotechnology, Forensic Biotechnology, Others) |
|
Countries Covered |
U.S., Canada, Mexico. U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific , South Africa, Saudi Arabia, U.A.E., Israel, Egypt and Rest of Middle East and Africa, Brazil, Argentina and Rest of South America |
|
Market Players Covered |
JADBio (U.S.), Gnosis Data Analysis (Israel), Fios Genomics (U.K.), SOPHiA GENETICS (Switzerland), Biomax Informatics Inc. (U.S.), DNASTAR (U.S.), Ardigen (Parent Company Selvita Group) (Poland), Source BioScience (U.K.), QIAGEN (Germany), NeoGenomics Laboratories (U.S.), CelbridgeScience (U.S), Eurofins Scientific (Luxembourg), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Insilico Medicine (U.S.), Strand Life Sciences (India), Dassault Systèmes (France), iNDX.Ai (U.S.), Paige AI, Inc. (U.S.), SomaLogic Operating Co., Inc. (U.S.), and among others |
|
Market Opportunities |
|
Market Definition
Bioinformatics is a sub-discipline that has to do with the analysis of sequences of biological molecules. It usually refers to genes, DNA, RNA, or protein and is particularly useful in comparing genes and other sequences in proteins and different sequences within an organism or between organisms, looking at the evolutionary relationships between organisms and using the patterns that exist across DNA and protein sequences to figure out what their function is.
Bioinformatics combines computer programming, big data and molecular biology, which enables scientists to understand and identify patterns in biological data. It is particularly useful in studying genomes and DNA sequencing, as it allows scientists to organize large amounts of data.
From genetics to toxicology to mycology and radiobiology, there are scores of branches of biology to specialize in. And out of the many, bioinformatics is one of the intriguing fields which enables you to identify, evaluate, store and retrieve biological information. Being an interdisciplinary field of study, it incorporates various applications of computer science, statistics and biology to develop software applications for understanding biological data like DNA sequencing, protein analysis, evolutionary genetics and others.
In the coming future, important decisions related to bioinformatics on drug discovery will be made by individuals who not only understand biology but can also use the bioinformatics tools and the knowledge they release to develop hypotheses and identify the quality target.
Global AI in Bioinformatics Market Dynamics
Drivers
- Growing demand for bioinformatics
As genomics focused, pharmacology continues to play a greater role in the treatment of various chronic diseases, especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight into molecular underpinnings of individual tumors and specific receptors. Informatics is essential in biological research, which involves biologists who learn programming, or computer programmers, mathematicians, or database managers to learn the foundations of biology.
- Reduction in the genetic sequencing cost
The strong demand for decreasing the cost of genomics and biomarker prediction has contributed to the creation of high-throughput genome sequencing, which often goes by the name next-generation sequencing (NGS). Thousands or millions of sequences in a single bioinformatics cycle are generated simultaneously. Dramatic upgrades to industrial NGS technologies have culminated in dramatic cutbacks in DNA sequencing cost-per-base. Thus recently, the main sequencing techniques have become the key subject of research, with sample design optimization taking a secondary function.
- Increasing public-private sector funding for bioinformatics
In order to improve the workflow for bioinformatics, the federal agencies, the public and the private agencies are providing funds in order to carry out bioinformatics projects and to scientists for research purposes. It is important to approach possible funders with a clear proposal and strategy of what is to be achieved in terms of bioinformatics capacity building in the institution as well as the intended outputs and outcomes. Many government bodies and private organizations across the globe are increasingly investing in the field of bioinformatics. These investments have largely resulted in data and technological advancements in bioinformatics services, which, in turn, have improved the quality of these services.
Opportunities
- Strategic initiatives of key players
The dramatic rise in the quality of research coupled with increasing research opportunities is because of various strategic initiatives taken by key market players. They are taking initiatives such as product launches, collaborations, mergers, acquisitions and many more over the years and are expected to lead and create more opportunities in the market.
By successfully working with new technology firms to ensure continued growth, creativity and viability in the industry, healthcare product suppliers have a huge opportunity. Health enterprises that implement technology-enabled technologies will explore new modes of goods for patient care, streamline processes and engage patients more.
Companies to discover and develop advanced bioinformatics products and these companies are launching new initiatives and collaborating with other key players to deliver more reliable results and services.
- Advancement in bioinformatics technology
The dimensions and cost of bioinformatics platforms and instruments are decreasing, allowing easier uptake by public health laboratories. Although currently, AI based bioinformatics requires highly specialized equipment and substantially skilled staff to analyze the data, it is unlikely that the bioinformatics revolution has finished. With rising technology, up-gradation of instruments and techniques is also needed, moreover, the bioinformatics market has a vast potential to upgrade in various applications and there are high chances of the advancement of bioinformatics techniques in the forecasted period.
Restraints/Challenges
- High cost of instrumentation
The cost of the device plays a major factor in the market. The AI based bioinformatics instrument is highly sophisticated and needs high validation and other specification, which increase. Genomics instruments are also equipped with advanced features and functionalities and are thus priced at a premium, ranging between USD 10–20 million. As pharmaceutical companies and research laboratories require many such systems, their capital expenditure on procuring multiple genomic instruments is very high. In the case of small and medium-sized pharmaceutical companies and research laboratories, it is not feasible for them to make such high investments in multiple genomics instruments. Hence, the high cost of AI based equipment is expected to restrain the market growth.
- Lack of skilled professionals to perform AI based bioinformatics technology
One of biology's most rapidly developing fields of study is bioinformatics, which involves developing and using computational tools for collecting, archiving, organizing, analyzing, and visualizing biological data. The advancement of technology has made it possible to reach the level of next-generation analysis from conventional data analysis methods. The advancement of the technology of bioinformatics requires various skill sets for its handling. As the bioinformatics platforms are highly automated and costly machines, the improper handling of such machines can damage their parts which can hamper achieving analysis and visualisation of biological data. Thereby, it will proportionally hamper the result of data processing. The dearth of skilled professionals having adequate skills and knowledge to perform next-generation sequencing, therefore, hampers the growth of the market.
This AI in bioinformatics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the AI in bioinformatics market contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In June 2022, SOPHiA GENETICS, a leader in data-driven medicine, announced at the ESHG Conference in Vienna that it has achieved CE-IVD certification for the analytical functionality supported by its cloud-based SOPHiA DDM™ Platform, an accessory to diagnostic applications. With this certification, the SOPHiA DDM™ Platform is now IVD-ready to support all applications and modules designed for diagnostic purposes in the European Union and other markets recognizing this certification. This has helped the company to increase its global presence in the market
- In December 2021, JADBio and BioLizard announced their partnership. BioLizard is agile bioinformatics and AI/ML company globally servicing clients in the life sciences, biotechnology and pharmaceutical industries. JADBio is a robust Automated Machine Learning platform that allows intuitive, timely and interactive creation of ML predictive models on BioMedical and Multi-omics data while allowing for knowledge (biomarker signature) discovery through its vast range of reporting and analysis. This has helped the company to expand its products and services portfolio in the market.
Global AI in Bioinformatics Market Scope
The AI in bioinformatics market is segmented on the basis of offering, type, products and services, application and sector. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Offering
- Services
- Software
- Others
Type
- Machine Learning
- Deep Learning
- Others
Products and Services
- Bioinformatics Services
- Bioinformatics Platforms
- Knowledge Management Tools
Application
- Genomics
- Chemoinformatics & Drug Design
- Proteomics
- DNA Sequencing
- System Biology
- Transcriptomics
- Text Mining
- Microarrays
- Metabolomics
- Others
Sector
- Medical Biotechnology
- Animal Biotechnology
- Plant Biotechnology
- Environmental Biotechnology
- Forensic Biotechnology
- Others
Global AI in Bioinformatics Analysis/Insights
The AI in bioinformatics market is analyzed and market size insights and trends are provided by country, offering, type, products and services, application and sector as referenced above.
The countries covered in the AI in bioinformatics market report are U.S., Canada, Mexico in North America, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, rest of Europe in Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, rest of Asia-Pacific in Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and rest of Middle East and Africa (MEA) in Middle East and Africa, Brazil, Argentina and rest of South America in South America.
North America is expected to dominate the global AI in bioinformatics market due to the rising demand for advanced technology and drug development & design, which have accelerated the market growth. To cope with the increasing demand, companies and market players are initiating various strategies such as product launch, advancement, acquisition agreements and others which is expected to dive the market growth.
Asia-Pacific is expected to show significant growth in AI in Bioinformatics market during the forecast period of 2023 to 203o due to rapidly increasing government investments in healthcare infrastructure and AI research.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and AI in Bioinformatics Market Share Analysis
The AI in bioinformatics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus on the AI in bioinformatics market.
The major players covered in the AI in bioinformatics market report are:
- JADBio (U.S.)
- Gnosis Data Analysis (Israel)
- Fios Genomics (U.K.)
- SOPHiA GENETICS (Switzerland)
- Biomax Informatics Inc. (U.S.)
- DNASTAR (U.S.)
- Ardigen (Parent Company Selvita Group) (Poland)
- Source BioScience (U.K.)
- QIAGEN (Germany)
- NeoGenomics Laboratories (U.S.)
- CelbridgeScience (U.S.)
- Eurofins Scientific (Luxembourg)
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific, Inc. (U.S.)
- Insilico Medicine (U.S.)
- Strand Life Sciences (India)
- Dassault Systèmes (France)
- iNDX.Ai (U.S.)
- Paige AI, Inc. (U.S.)
- SomaLogic Operating Co., Inc. (U.S.)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL AI IN BIOINFORMATICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL AI IN BIOINFORMATICS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET GUIDE
2.2.4 COMPANY POSITIONING GRID
2.2.5 COMPANY MARKET SHARE ANALYSIS
2.2.6 MULTIVARIATE MODELLING
2.2.7 TOP TO BOTTOM ANALYSIS
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 VENDOR SHARE ANALYSIS
2.2.10 SALES VOLUME
2.2.11 EPIDEMIOLOGY MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL AI IN BIOINFORMATICS MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER'S FIVE FORCES MODEL
6. INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYSIS AND RECOMMENDATIONS
7. INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8. COST ANALYSIS BREAKDOWN
9. TECHNOLOGY ROADMAP
10. INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11. REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12. REIMBURSEMENT FRAMEWORK
13. OPPUTUNITY MAP ANALYSIS
14. INSTALLED BASE DATA
15. VALUE CHAIN ANALYSIS
16. HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.10 ECONOMIC DEVELOPMENT
17. GLOBAL AI IN BIOINFORMATICS MARKET, BY OFFERING
17.1 OVERVIEW
17.2 SOFTWARE
17.2.1 BY MODE
17.2.1.1. INTEGRATED
17.2.1.2. STANDALONE
17.2.2 BY DEPLOYMENT MODE
17.2.2.1. WEB-BASED
17.2.2.2. CLOUD-BASED
17.2.2.3. ON PREMISE
17.3 SERVICES
17.4 HARDWARE
18. GLOBAL AI IN BIOINFORMATICS MARKET , BY PRODUCT AND SERVICES
18.1 OVERVIEW
18.2 KNOWLEDGE MANAGEMENT TOOLS
18.2.1 GENERALISED KNOWLEDGE MANAGEMENT TOOLS
18.2.2 SPECIALISED KNOWLEDGE MANAGEMENT TOOLS
18.3 BIOINFORMATICS PLATFORMS
18.3.1 SEQUENCE ANALYSIS PLATFORMS
18.3.2 SEQUENCE ALIGNMENT PLATFORMS
18.3.3 SEQUENCE MANIPULATION PLATFORMS
18.3.4 STRUCTURAL ANALYSIS PLATFORMS
18.3.5 OTHERS
18.4 BIOINFORMATICS SERVICES
18.4.1 SEQUENCING SERVICES
18.4.2 DATABASE MANAGEMENT
18.4.3 DATA ANALYSIS
18.4.4 OTHERS
19. GLOBAL AI IN BIOINFORMATICS MARKET , BY TYPE
19.1 OVERVIEW
19.2 MACHINE LEARNING
19.2.1 SUPERVISED LEARNING
19.2.2 UNSUPERVISED LEARNING
19.3 DEEP LEARNING
19.4 NATURAL LANGUAGE PROCESSING (NLP)
19.5 NEURAL NETWORKS
19.6 OTHERS
20. GLOBAL AI IN BIOINFORMATICS MARKET , BY APPLICATION
20.1 OVERVIEW
20.2 GENOMICS
20.2.1 BY TYPE
20.2.1.1. SEQUENCE ANALYSIS
20.2.1.1.1. DNA
20.2.1.1.2. RNA
20.2.1.2. GENE EXPRESSION ANALYSIS AND CLUSTERING
20.2.1.3. VIRAL GENE-VARIANT REPORTING
20.2.1.4. OTHERS
20.2.2 BY OFFERING
20.2.2.1. SOFTWARE
20.2.2.1.1. BY MODE
20.2.2.1.1.1 INTEGRATED
20.2.2.1.1.2 STANDALONE
20.2.2.1.2. BY DEPLOYMENT MODE
20.2.2.1.2.1 WEB-BASED
20.2.2.1.2.2 CLOUD-BASED
20.2.2.1.2.3 ON PREMISE
20.2.2.2. SERVICES
20.2.2.3. HARDWARE
20.3 MICROARRAYS
20.3.1 SOFTWARE
20.3.1.1. BY MODE
20.3.1.1.1. INTEGRATED
20.3.1.1.2. STANDALONE
20.3.1.2. BY DEPLOYMENT MODE
20.3.1.2.1. WEB-BASED
20.3.1.2.2. CLOUD-BASED
20.3.1.2.3. ON PREMISE
20.3.2 SERVICES
20.3.3 HARDWARE
20.4 STRUCTURALBIOLOGY
20.4.1 SOFTWARE
20.4.1.1. BY MODE
20.4.1.1.1. INTEGRATED
20.4.1.1.2. STANDALONE
20.4.1.2. BY DEPLOYMENT MODE
20.4.1.2.1. WEB-BASED
20.4.1.2.2. CLOUD-BASED
20.4.1.2.3. ON PREMISE
20.4.2 SERVICES
20.4.3 HARDWARE
20.5 CHEMOINFORMATICS & DRUG DESIGN
20.5.1 BY PHASE
20.5.1.1. PRE-CLINICAL
20.5.1.2. HIV AND HEPATITIS C (HCV) PROTEASE CLEAVAGE PREDICTION
20.5.1.3. OTHERS
20.5.2 BY OFFERING
20.5.2.1. SOFTWARE
20.5.2.1.1. BY MODE
20.5.2.1.1.1 INTEGRATED
20.5.2.1.1.2 STANDALONE
20.5.2.1.2. BY DEPLOYMENT MODE
20.5.2.1.2.1 WEB-BASED
20.5.2.1.2.2 CLOUD-BASED
20.5.2.1.2.3 ON PREMISE
20.5.2.2. SERVICES
20.5.2.3. HARDWARE
20.6 PROTEOMICS
20.6.1 SOFTWARE
20.6.1.1. BY MODE
20.6.1.1.1. INTEGRATED
20.6.1.1.2. STANDALONE
20.6.1.2. BY DEPLOYMENT MODE
20.6.1.2.1. WEB-BASED
20.6.1.2.2. CLOUD-BASED
20.6.1.2.3. ON PREMISE
20.6.2 SERVICES
20.6.3 HARDWARE
20.7 TRANSCRIPTOMICS
20.7.1 SOFTWARE
20.7.1.1. BY MODE
20.7.1.1.1. INTEGRATED
20.7.1.1.2. STANDALONE
20.7.1.2. BY DEPLOYMENT MODE
20.7.1.2.1. WEB-BASED
20.7.1.2.2. CLOUD-BASED
20.7.1.2.3. ON PREMISE
20.7.2 SERVICES
20.7.3 HARDWARE
20.8 METABOLOMICS
20.8.1 SOFTWARE
20.8.1.1. BY MODE
20.8.1.1.1. INTEGRATED
20.8.1.1.2. STANDALONE
20.8.1.2. BY DEPLOYMENT MODE
20.8.1.2.1. WEB-BASED
20.8.1.2.2. CLOUD-BASED
20.8.1.2.3. ON PREMISE
20.8.2 SERVICES
20.8.3 HARDWARE
20.9 PRECISION MEDICINE
20.9.1 SOFTWARE
20.9.1.1. BY MODE
20.9.1.1.1. INTEGRATED
20.9.1.1.2. STANDALONE
20.9.1.2. BY DEPLOYMENT MODE
20.9.1.2.1. WEB-BASED
20.9.1.2.2. CLOUD-BASED
20.9.1.2.3. ON PREMISE
20.9.2 SERVICES
20.9.3 HARDWARE
20.10 MOLECULAR MODELING
20.10.1 SOFTWARE
20.10.1.1. BY MODE
20.10.1.1.1. INTEGRATED
20.10.1.1.2. STANDALONE
20.10.1.2. BY DEPLOYMENT MODE
20.10.1.2.1. WEB-BASED
20.10.1.2.2. CLOUD-BASED
20.10.1.2.3. ON PREMISE
20.10.2 SERVICES
20.10.3 HARDWARE
20.11 OTHERS
21. GLOBAL AI IN BIOINFORMATICS MARKET , BY SECTOR
21.1 OVERVIEW
21.2 MEDICAL BIOTECHNOLOGY
21.2.1 SOFTWARE
21.2.1.1. BY MODE
21.2.1.1.1. INTEGRATED
21.2.1.1.2. STANDALONE
21.2.1.2. BY DEPLOYMENT MODE
21.2.1.2.1. WEB-BASED
21.2.1.2.2. CLOUD-BASED
21.2.1.2.3. ON PREMISE
21.2.2 SERVICES
21.2.3 HARDWARE
21.3 ANIMAL BIOTECHNOLOGY
21.3.1 SOFTWARE
21.3.1.1. BY MODE
21.3.1.1.1. INTEGRATED
21.3.1.1.2. STANDALONE
21.3.1.2. BY DEPLOYMENT MODE
21.3.1.2.1. WEB-BASED
21.3.1.2.2. CLOUD-BASED
21.3.1.2.3. ON PREMISE
21.3.2 SERVICES
21.3.3 HARDWARE
21.4 PLANT BIOTECHNOLOGY
21.4.1 SOFTWARE
21.4.1.1. BY MODE
21.4.1.1.1. INTEGRATED
21.4.1.1.2. STANDALONE
21.4.1.2. BY DEPLOYMENT MODE
21.4.1.2.1. WEB-BASED
21.4.1.2.2. CLOUD-BASED
21.4.1.2.3. ON PREMISE
21.4.2 SERVICES
21.4.3 HARDWARE
21.5 ENVIRONMENTAL BIOTECHNOLOGY
21.5.1 SOFTWARE
21.5.1.1. BY MODE
21.5.1.1.1. INTEGRATED
21.5.1.1.2. STANDALONE
21.5.1.2. BY DEPLOYMENT MODE
21.5.1.2.1. WEB-BASED
21.5.1.2.2. CLOUD-BASED
21.5.1.2.3. ON PREMISE
21.5.2 SERVICES
21.5.3 HARDWARE
21.6 FORENSIC BIOTECHNOLOGY
21.6.1 SOFTWARE
21.6.1.1. BY MODE
21.6.1.1.1. INTEGRATED
21.6.1.1.2. STANDALONE
21.6.1.2. BY DEPLOYMENT MODE
21.6.1.2.1. WEB-BASED
21.6.1.2.2. CLOUD-BASED
21.6.1.2.3. ON PREMISE
21.6.2 SERVICES
21.6.3 HARDWARE
21.7 OTHERS
22. GLOBAL AI IN BIOINFORMATICS MARKET , BY END USER
22.1 OVERVIEW
22.2 PHARMA AND BIOPHARMA COMPANIES
22.2.1 SOFTWARE
22.2.1.1. BY MODE
22.2.1.1.1. INTEGRATED
22.2.1.1.2. STANDALONE
22.2.1.2. BY DEPLOYMENT MODE
22.2.1.2.1. WEB-BASED
22.2.1.2.2. CLOUD-BASED
22.2.1.2.3. ON PREMISE
22.2.2 SERVICES
22.2.3 HARDWARE
22.3 BIOTECH COMPANIES
22.3.1 SOFTWARE
22.3.1.1. BY MODE
22.3.1.1.1. INTEGRATED
22.3.1.1.2. STANDALONE
22.3.1.2. BY DEPLOYMENT MODE
22.3.1.2.1. WEB-BASED
22.3.1.2.2. CLOUD-BASED
22.3.1.2.3. ON PREMISE
22.3.2 SERVICES
22.3.3 HARDWARE
22.4 GOVERNMENT AGENCIES
22.4.1 SOFTWARE
22.4.1.1. BY MODE
22.4.1.1.1. INTEGRATED
22.4.1.1.2. STANDALONE
22.4.1.2. BY DEPLOYMENT MODE
22.4.1.2.1. WEB-BASED
22.4.1.2.2. CLOUD-BASED
22.4.1.2.3. ON PREMISE
22.4.2 SERVICES
22.4.3 HARDWARE
22.5 LABORATORIES
22.5.1 SOFTWARE
22.5.1.1. BY MODE
22.5.1.1.1. INTEGRATED
22.5.1.1.2. STANDALONE
22.5.1.2. BY DEPLOYMENT MODE
22.5.1.2.1. WEB-BASED
22.5.1.2.2. CLOUD-BASED
22.5.1.2.3. ON PREMISE
22.5.2 SERVICES
22.5.3 HARDWARE
22.6 RESEARCH AND ACADEMIC INSTITUTES
22.6.1 SOFTWARE
22.6.1.1. BY MODE
22.6.1.1.1. INTEGRATED
22.6.1.1.2. STANDALONE
22.6.1.2. BY DEPLOYMENT MODE
22.6.1.2.1. WEB-BASED
22.6.1.2.2. CLOUD-BASED
22.6.1.2.3. ON PREMISE
22.6.2 SERVICES
22.6.3 HARDWARE
22.7 OTHERS
23. GLOBAL AI IN BIOINFORMATICS MARKET , BY REGION
GLOBAL AI IN BIOINFORMATICS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1 NORTH AMERICA
23.1.1 U.S.
23.1.2 CANADA
23.1.3 MEXICO
23.2 EUROPE
23.2.1 GERMANY
23.2.2 FRANCE
23.2.3 U.K.
23.2.4 HUNGARY
23.2.5 LITHUANIA
23.2.6 AUSTRIA
23.2.7 IRELAND
23.2.8 NORWAY
23.2.9 POLAND
23.2.10 ITALY
23.2.11 SPAIN
23.2.12 RUSSIA
23.2.13 TURKEY
23.2.14 NETHERLANDS
23.2.15 SWITZERLAND
23.2.16 REST OF EUROPE
23.3 ASIA-PACIFIC
23.3.1 JAPAN
23.3.2 CHINA
23.3.3 SOUTH KOREA
23.3.4 INDIA
23.3.5 SINGAPORE
23.3.6 THAILAND
23.3.7 INDONESIA
23.3.8 MALAYSIA
23.3.9 PHILIPPINE
23.3.10 AUSTRALIA
23.3.11 NEW ZEALAND
23.3.12 VIETNAM
23.3.13 TAIWAN
23.3.14 REST OF ASIA-PACIFIC
23.4 SOUTH AMERICA
23.4.1 BRAZIL
23.4.2 ARGENTINA
23.4.3 REST OF SOUTH AMERICA
23.5 MIDDLE EAST AND AFRICA
23.5.1 SOUTH AFRICA
23.5.2 SAUDI ARABIA
23.5.3 UAE
23.5.4 EGYPT
23.5.5 KUWAIT
23.5.6 ISRAEL
23.5.7 REST OF MIDDLE EAST AND AFRICA
23.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24. GLOBAL AI IN BIOINFORMATICS MARKET , SWOT AND DBMR ANALYSIS
25. GLOBAL AI IN BIOINFORMATICS MARKET , COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
25.5 MERGERS & ACQUISITIONS
25.6 NEW PRODUCT DEVELOPMENT & APPROVALS
25.7 EXPANSIONS
25.8 REGULATORY CHANGES
25.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26. GLOBAL AI IN BIOINFORMATICS MARKET , COMPANY PROFILE
26.1 ILLUMINA, INC
26.1.1 COMPANY OVERVIEW
26.1.2 GEOGRAPHIC PRESENCE
26.1.3 REVENUE ANALYSIS
26.1.4 PRODUCT PORTFOLIO
26.1.5 RECENT DEVELOPEMENTS
26.2 DASSAULT SYSTÈMES
26.2.1 COMPANY OVERVIEW
26.2.2 GEOGRAPHIC PRESENCE
26.2.3 REVENUE ANALYSIS
26.2.4 PRODUCT PORTFOLIO
26.2.5 RECENT DEVELOPEMENTS
26.3 AGILENT TECHNOLOGIES, INC + NVIDIA + AWS
26.3.1 COMPANY OVERVIEW
26.3.2 GEOGRAPHIC PRESENCE
26.3.3 REVENUE ANALYSIS
26.3.4 PRODUCT PORTFOLIO
26.3.5 RECENT DEVELOPEMENTS
26.4 QIAGEN
26.4.1 COMPANY OVERVIEW
26.4.2 GEOGRAPHIC PRESENCE
26.4.3 REVENUE ANALYSIS
26.4.4 PRODUCT PORTFOLIO
26.4.5 RECENT DEVELOPEMENTS
26.5 GNOSIS DATA ANALYSIS
26.5.1 COMPANY OVERVIEW
26.5.2 GEOGRAPHIC PRESENCE
26.5.3 REVENUE ANALYSIS
26.5.4 PRODUCT PORTFOLIO
26.5.5 RECENT DEVELOPEMENTS
26.6 FIOS GENOMICS
26.6.1 COMPANY OVERVIEW
26.6.2 GEOGRAPHIC PRESENCE
26.6.3 REVENUE ANALYSIS
26.6.4 PRODUCT PORTFOLIO
26.6.5 RECENT DEVELOPEMENTS
26.7 JADBIO – GNOSIS DA S.A.
26.7.1 COMPANY OVERVIEW
26.7.2 GEOGRAPHIC PRESENCE
26.7.3 REVENUE ANALYSIS
26.7.4 PRODUCT PORTFOLIO
26.7.5 RECENT DEVELOPEMENTS
26.8 DNASTAR
26.8.1 COMPANY OVERVIEW
26.8.2 GEOGRAPHIC PRESENCE
26.8.3 REVENUE ANALYSIS
26.8.4 PRODUCT PORTFOLIO
26.8.5 RECENT DEVELOPEMENTS
26.9 SOPHIA GENETICS
26.9.1 COMPANY OVERVIEW
26.9.2 GEOGRAPHIC PRESENCE
26.9.3 REVENUE ANALYSIS
26.9.4 PRODUCT PORTFOLIO
26.9.5 RECENT DEVELOPEMENTS
26.10 BIOMAX INFORMATICS AG + MOLECULAR NETWORKS GMBH
26.10.1 COMPANY OVERVIEW
26.10.2 GEOGRAPHIC PRESENCE
26.10.3 REVENUE ANALYSIS
26.10.4 PRODUCT PORTFOLIO
26.10.5 RECENT DEVELOPEMENTS
26.11 ARDIGEN
26.11.1 COMPANY OVERVIEW
26.11.2 GEOGRAPHIC PRESENCE
26.11.3 REVENUE ANALYSIS
26.11.4 PRODUCT PORTFOLIO
26.11.5 RECENT DEVELOPEMENTS
26.12 SOURCE GENOMICS
26.12.1 COMPANY OVERVIEW
26.12.2 GEOGRAPHIC PRESENCE
26.12.3 REVENUE ANALYSIS
26.12.4 PRODUCT PORTFOLIO
26.12.5 RECENT DEVELOPEMENTS
26.13 EUROFINS SCIENTIFIC
26.13.1 COMPANY OVERVIEW
26.13.2 GEOGRAPHIC PRESENCE
26.13.3 REVENUE ANALYSIS
26.13.4 PRODUCT PORTFOLIO
26.13.5 RECENT DEVELOPEMENTS
26.14 INSILICO MEDICINE
26.14.1 COMPANY OVERVIEW
26.14.2 GEOGRAPHIC PRESENCE
26.14.3 REVENUE ANALYSIS
26.14.4 PRODUCT PORTFOLIO
26.14.5 RECENT DEVELOPEMENTS
26.15 NEOGENOMICS LABORATORIES
26.15.1 COMPANY OVERVIEW
26.15.2 GEOGRAPHIC PRESENCE
26.15.3 REVENUE ANALYSIS
26.15.4 PRODUCT PORTFOLIO
26.15.5 RECENT DEVELOPEMENTS
26.16 GENEDATA AG
26.16.1 COMPANY OVERVIEW
26.16.2 GEOGRAPHIC PRESENCE
26.16.3 REVENUE ANALYSIS
26.16.4 PRODUCT PORTFOLIO
26.16.5 RECENT DEVELOPEMENTS
26.17 PLISADE BIO. + STRAND LIFE SCIENCES
26.17.1 COMPANY OVERVIEW
26.17.2 GEOGRAPHIC PRESENCE
26.17.3 REVENUE ANALYSIS
26.17.4 PRODUCT PORTFOLIO
26.17.5 RECENT DEVELOPEMENTS
26.18 INDX.AI.
26.18.1 COMPANY OVERVIEW
26.18.2 GEOGRAPHIC PRESENCE
26.18.3 REVENUE ANALYSIS
26.18.4 PRODUCT PORTFOLIO
26.18.5 RECENT DEVELOPEMENTS
26.19 PAIGE AI, INC.
26.19.1 COMPANY OVERVIEW
26.19.2 GEOGRAPHIC PRESENCE
26.19.3 REVENUE ANALYSIS
26.19.4 PRODUCT PORTFOLIO
26.19.5 RECENT DEVELOPEMENTS
26.20 OWKIN
26.20.1 COMPANY OVERVIEW
26.20.2 GEOGRAPHIC PRESENCE
26.20.3 REVENUE ANALYSIS
26.20.4 PRODUCT PORTFOLIO
26.20.5 RECENT DEVELOPEMENTS
26.21 INSITRO
26.21.1 COMPANY OVERVIEW
26.21.2 GEOGRAPHIC PRESENCE
26.21.3 REVENUE ANALYSIS
26.21.4 PRODUCT PORTFOLIO
26.21.5 RECENT DEVELOPEMENTS
26.22 SHANGHAI ARTIFICIAL INTELLIGENCE LABORATORY
26.22.1 COMPANY OVERVIEW
26.22.2 GEOGRAPHIC PRESENCE
26.22.3 REVENUE ANALYSIS
26.22.4 PRODUCT PORTFOLIO
26.22.5 RECENT DEVELOPEMENTS
26.23 IONLACE
26.23.1 COMPANY OVERVIEW
26.23.2 GEOGRAPHIC PRESENCE
26.23.3 REVENUE ANALYSIS
26.23.4 PRODUCT PORTFOLIO
26.23.5 RECENT DEVELOPEMENTS
26.24 TAMARIND BIO
26.24.1 COMPANY OVERVIEW
26.24.2 GEOGRAPHIC PRESENCE
26.24.3 REVENUE ANALYSIS
26.24.4 PRODUCT PORTFOLIO
26.24.5 RECENT DEVELOPEMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
27. RELATED REPORTS
28. QUESTIONNAIRE
29. CONCLUSION
30. DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
